Health
Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients – News-Medical.Net
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow. They can occur spontaneously or secondary to treatment for other cancers, so called therapy related disease, which is frequently associated with a mutation of the tumor suppressor gene TP53. Standard treatment for these patients includes hypomethylating agents such as azacitidine or decitabine but unfortunately outcomes are very poor.
Patients with TP53-mutant disease, which is…
-
Noosa News22 hours agoPolice appeal for information over suspected link in torture and murder cases
-
Noosa News16 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General20 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News22 hours agoTips to improve engagement – Proctor